CO7170170A2 - Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio - Google Patents

Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio

Info

Publication number
CO7170170A2
CO7170170A2 CO15008510A CO15008510A CO7170170A2 CO 7170170 A2 CO7170170 A2 CO 7170170A2 CO 15008510 A CO15008510 A CO 15008510A CO 15008510 A CO15008510 A CO 15008510A CO 7170170 A2 CO7170170 A2 CO 7170170A2
Authority
CO
Colombia
Prior art keywords
inhibitors
potassium channel
activated potassium
calcium activated
oxazolidinone derivatives
Prior art date
Application number
CO15008510A
Other languages
English (en)
Inventor
Luke Green
Haiyan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO7170170A2 publication Critical patent/CO7170170A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos que tienen la fórmula general l: en la que n, R, R, R, Ry Rtienen los significados aquí definidos, una composición que contiene los compuestos y métodos de uso de los compuestos. 1 2a 2b 3a 3b
CO15008510A 2012-10-29 2015-01-16 Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio CO7170170A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29

Publications (1)

Publication Number Publication Date
CO7170170A2 true CO7170170A2 (es) 2015-01-28

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15008510A CO7170170A2 (es) 2012-10-29 2015-01-16 Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado por calcio

Country Status (24)

Country Link
US (1) US9611232B2 (es)
EP (1) EP2912034B1 (es)
JP (1) JP6216385B2 (es)
KR (1) KR20150075091A (es)
CN (1) CN104781256B (es)
AR (1) AR093168A1 (es)
AU (1) AU2013339607A1 (es)
BR (1) BR112015003996A2 (es)
CA (1) CA2879249A1 (es)
CL (1) CL2015000906A1 (es)
CO (1) CO7170170A2 (es)
CR (1) CR20150159A (es)
EA (1) EA026161B1 (es)
HK (1) HK1207632A1 (es)
IL (1) IL237331A0 (es)
IN (1) IN2015DN00961A (es)
MA (1) MA38135B1 (es)
MX (1) MX2015002399A (es)
PE (1) PE20150775A1 (es)
PH (1) PH12015500292A1 (es)
SG (1) SG11201500585XA (es)
TW (1) TW201422596A (es)
UA (1) UA114649C2 (es)
WO (1) WO2014067861A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
EP3941903A1 (en) 2019-03-22 2022-01-26 Saniona A/S Novel potassium channel inhibitors
JP2023544520A (ja) 2020-09-22 2023-10-24 サニオナ エー／エス 新規カリウムチャネル阻害剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
EP0215435B1 (en) * 1985-09-09 1993-03-03 Otsuka Pharmaceutical Co., Ltd. 2-oxa-isocephem compounds, compositions containing same and processes for preparing same
EP0557408A4 (en) * 1990-11-06 1993-10-27 Smith-Kline Beecham Corporation Imidazolidinone compounds
DE4439846A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
EP1144387A1 (en) * 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
EP1254895B1 (en) * 2000-01-20 2007-05-23 Eisai R&D Management Co., Ltd. Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
US6903089B1 (en) * 2000-11-22 2005-06-07 Bayer Aktiengesellschaft Lactam-substituted pyrazolopyridine derivatives
US7879839B2 (en) 2004-07-29 2011-02-01 Merck Sharp & Dohme Corp. Potassium channel inhibitors
DE102004060229A1 (de) * 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (en) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
AR074558A1 (es) * 2008-12-12 2011-01-26 Solvay Pharm Bv Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3
WO2010123997A1 (en) * 2009-04-22 2010-10-28 Achaogen, Inc. Carbacephem beta-lactam antibiotics

Also Published As

Publication number Publication date
US9611232B2 (en) 2017-04-04
TW201422596A (zh) 2014-06-16
PE20150775A1 (es) 2015-05-21
CN104781256B (zh) 2017-09-29
MA38135A2 (fr) 2016-11-30
IN2015DN00961A (es) 2015-06-12
SG11201500585XA (en) 2015-04-29
HK1207632A1 (en) 2016-02-05
CA2879249A1 (en) 2014-05-08
PH12015500292A1 (en) 2015-04-20
JP6216385B2 (ja) 2017-10-18
IL237331A0 (en) 2015-04-30
BR112015003996A2 (pt) 2017-07-04
MA38135B1 (fr) 2018-11-30
KR20150075091A (ko) 2015-07-02
EA201590729A1 (ru) 2015-07-30
US20150246894A1 (en) 2015-09-03
MX2015002399A (es) 2015-06-10
AR093168A1 (es) 2015-05-20
EA026161B1 (ru) 2017-03-31
CN104781256A (zh) 2015-07-15
AU2013339607A1 (en) 2015-02-05
EP2912034A1 (en) 2015-09-02
WO2014067861A1 (en) 2014-05-08
UA114649C2 (uk) 2017-07-10
JP2015535231A (ja) 2015-12-10
EP2912034B1 (en) 2017-05-31
CL2015000906A1 (es) 2015-09-11
CR20150159A (es) 2015-04-30

Similar Documents

Publication Publication Date Title
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
CR20160419A (es) Nuevos compuestos biciclicos
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20150250A (es) Nuevos derivados de piridina
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
MX2021000189A (es) Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias.
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20160016A (es) Pirazolpiridinas sustituidas
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03